Latest article
Lilly’s tirzepatide beats Ozempic in head-to-head kind 2 diabetes trial
Eli Lilly announced that its investigated GIP and GLP-1 inhibitor tirzepatide has demonstrated superiority over Novo Nordisk's Ozempic in a Phase III study.The SURPASS-2...
‘Diabetes ups sufferers’ black fungus threat’ | Lucknow Information
Disinfection is in progress during the curfew in CovidLUCKNOW: Uncontrolled diabetes is the most common risk factor for acquiring black fungus infection or mucormycosis,...
Important Oils Market Report 2021-2026
According to the latest report from the IMARC Group, the global essential oils market grew with a CAGR of around 7% in the period...